Brief: Kintor Pharmaceutical Says Pharma's Kx-826 Phase Iii Trial In China Reaches Primary Endpoint
18/03/2026 15:32
March 18 (Reuters) - Kintor Pharmaceutical Ltd 9939.HK: PHARMA'S KX-826 PHASE III TRIAL IN CHINA REACHES PRIMARY ENDPOINT Further company coverage: 9939.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kintor Pharmaceutical
See all newsBrief: Kintor Pharmaceutical Receives Invention Patent Grant For KT-939 In China
Brief: Kintor Pharmaceutical Says Ming Ming Cheung Resigns As CFO
Brief: Kintor Pharmaceutical Says CEO Via Wholly Owned Co Increases Shareholding By 2.51 Million Shares
Brief: Kintor Pharmaceutical Says YTD 2026 Sales Revenue At RMB34 Million
Brief: Kintor Pharmaceutical Says Pharma's Kx-826 Phase Iii Trial In China Reaches Primary Endpoint